Myeloid engraftment enhancement

Myeloid engraftment enhancement refers to the therapeutic facilitation and acceleration of hematopoietic stem and progenitor cell reconstitution within the bone marrow niche

Myeloid engraftment enhancement refers to the therapeutic facilitation and acceleration of hematopoietic stem and progenitor cell reconstitution within the bone marrow niche

This clinical objective specifically targets the hematopoietic and immune systems in patients undergoing autologous or allogeneic hematopoietic cell transplantation, who experience severe pancytopenia and profound immunosuppression following myeloablative or reduced-intensity conditioning regimens

Pathophysiologically, the pre-engraftment state is defined by critical absolute neutrophil depletion, leaving recipients vulnerable to life-threatening bacterial and fungal infections, mucosal injury, and prolonged hospitalization Enhancing myeloid engraftment aims to accelerate the biological trajectory of neutrophil recovery—classically defined as achieving a sustained absolute neutrophil count exceeding 500 cells/μL—thereby minimizing the duration of critical neutropenia and related transplan...

Enhancing myeloid engraftment aims to accelerate the biological trajectory of neutrophil recovery—classically defined as achieving a sustained absolute neutrophil count exceeding 500 cells/μL—thereby minimizing the duration of critical neutropenia and related transplant morbidity

Enhancing myeloid engraftment aims to accelerate the biological trajectory of neutrophil recovery—classically defined as achieving a sustained absolute neutrophil count exceeding 500 cells/μL—thereby minimizing the duration of critical neutropenia and related transplant morbidity